Member Info for Sangijuelas1

I haven't said news is not coming until next year.

Asthma, pancreatic cancer and Blautix updates are due in the next 2-3 weeks. Also hopefully the Bavencio trial will start.

I will be very interested to see the pancreatic cancer data having looked in more depth at the trial and the existing PC treatments, which are basically chemo prior to surgery.

Neither the P1 asthma safety data in 30 patients or the P1 pancreatic cancer trial in 15 patients will provide any support for the share price whatsoever.

The only possible catalysts are cash for Blautix or the 0518 data release which is not due until next year.

Phil, I really think you need to recover whatever funds you can from any stocks you hold and if you have a worthwhile sum stop trying to be a DIY investor and go get professional financial advice.

Share dealing is meant to be a bit of fun where we risk a little cash in the hope of getting a decent return but never so much that it causes us deep stress or anxiety.

Sometimes in life you have to admit defeat as life is short.

The recommended investment time frame for share dealing including equity funds is 5 years and they say don't invest in stocks if you need your money back sooner.

Micro RX platform with 9 drug candidates in pipeline discovered in 7 years

Blautix ready for P3 and talk of commercial manufacture in a US market conservatively estimated to be worth $2.4bn.

Partnerships in place with 2 mega pharmas in MSD and Pfizer and a mid market one Merck Kgaa

Massive opportunity for 0518 as combination therapy with other treatments including immune checkpoint inhibitors $27bn market. Next ICI collaboration likely to require upfront payment if the pharma wants to play with 0518.

Collaborations with top cancer research settings like MD Anderson and Imperial college.

Forthcoming trial for Parkinsons with a seat on the science advisory board of Michael J Fox Foundation and partnership with Parkinsons UK. Both collaborations will make patient recruitment a lot easier.

Funding in place until the end of 2022

Incredibly experienced board with heavyweights like Axel Glasmacher and Katrin Rupalla (check out their CVs)

Directors DP and AS own 10% of the company including further investments in the last placing at 110p

Vaccines collaboration with MSD with milestone payments potentially available of up to $1bn

A second generation oncology drug in pre clinical development already recognised for potential to make CAR-T therapies work in solid tumours (holy grail)

Manufacturing capacity in place for commercial production with 7 years worth of accumulated experience and expertise

With 2 partnerships in place with MSD and them owning nearly 5% surely the inevitable will be only a matter of time

Still about robins. I just see a lot of green boxes when I check the board now

Yeah I thought was shares as well.

However why is Kunwar getting paid £480k a year?

Duncan Peyton and Alex Stevenson the executive directors at 4D are both on £100k each as a benchmark.

I think it was you the other day Cloudy that said in the last interview GC said the Covid trial data would be out in January.

Only a week or so later in the updated presentation they are saying the data is due for Q2 next year.

It just seems to be a trail of broken promises.

Right but no one has seen any "science" to show that they will work in a way that is sufficiently safe and effective to achieve approval.

That's where the need to run trials comes in. You have to walk the walk because anyone can talk the talk.

Wow so GC is running the only small biotech in the world that can determine its own share price prior to any fund raise!

.

Jefferies gig is just a platform to showcase the company as a whole, to give them a chance to demonstrate to potential investors why they should pick 4D over the 700 other Nasdaq biotechs.

Having said that the asthma data is due for release. Should come this week.

Funny thing happened a while back.

I was chasing the company to find out why none of the trials they said they had done were registered on clinicaltrials.gov, the FDA register or any other internationally recognised registered. Also why no research published or any other public record of the trials.

I eventually got an email response after chasing them, which they also sent to their amateur PR guy Paul Spencer who published it on here.

It basically stated that they weren't obliged to register exploratory studies (although it is always best practice to do so) if they didn't want to.

They must have then told Paul Spencer that they had threatened me with legal action over my claims as he mentioned something of that nature the other day

Which obviously they never did as just an investor query

I think you have to be careful what you say as it could all be legit and maybe they are "doing their best '.

They are great at PR though.

They are exempt from US corp governance as a foreign issuer.

Think they are now subject to Bermuda's standards

I would say why only 13 staff?

4D have about 90.

It's not an RNS. Just a Reach news release which LSE flags as RNS

And I wouldn't sniff at participating in a conference run by the 8th biggest broker in the world.

You sounded pretty desperate back in February

RE: 4D Pharma TP09 Feb 2021 09:35
I just listened it and his chart is suggesting 1.60 by the end of next month :)). I would say there’s more chance of 1.60 before the end of this week. And closer to 2.60 at the end of next month. I don’t think his charts have picked up on the Nasdaq factor

So the MS Nasal Foralumab trial due to start in October has been dropped from the milestones. (You really need to ignore talk of a clinical readout from dosing of 1 patient-it is utterly meaningless)

The oral Phase 1b of Foralumab in Crohn’s has been pushed back to Q1 22 when it was supposed to start in October.

A phase 1a for diabetes in HEALTHY VOLUNTEERS. I thought they had already gathered data from healthy volunteers for safety previously. If they did they could go on to dosing in actual diabetes patients.

And they previously claimed to have done a P2 trial in Miliciclib so why the need to do another?

Do me a favour!

Credit to Devonlad on the other board.

List Biotherapeutics are investing $125m in a live biotherapeutic factory.

This sector is going to explode soon

https://www.businesswire.com/news/home/20211111005462/en/List-Biotherapeutics-Establishes-New-Microbiome-Manufacturing-Facility-in-Fishers

.